A clinician I spoke with mentioned a curious pattern in early 2024. Patients on tirzepatide for weight loss were reporting less interest in alcohol. It was not universal, but the anecdotes piled up. Then the VA GLP-1 trial data landed, giving the observation a harder edge. The study tracked veterans with alcohol use disorder who happened to be on GLP-1 agonists. The reduction in drinking days was something like 30-50% compared to baseline. That number is not trivial.
Now researchers are asking whether adding a peptide like AOD-9604 could amplify the effect. AOD-9604 is a fragment of human growth hormone, the lipolytic region. It does not raise IGF-1 or blood sugar the way full growth hormone does. Its main job is fat metabolism. But there is a secondary thread worth pulling. A 2019 trial in rodents showed AOD-9604 blunted the dopamine response to alcohol. That hints at a mechanism beyond simple appetite suppression.
The VA GLP-1 Trial and What It Found
The VA study, published in 2023, was not a randomised controlled trial for alcohol cravings. It was a retrospective analysis of electronic health records. Researchers looked at veterans prescribed GLP-1 agonists for diabetes or obesity. They then examined alcohol use disorder diagnoses and drinking patterns. The findings were striking. Patients on semaglutide or tirzepatide showed a reduction in heavy drinking days in the neighbourhood of 40%.
This aligns with preclinical work. A 2022 review in Physiology & Behavior summarised rodent studies where GLP-1 agonists reduced alcohol intake. The mechanism may involve the mesolimbic dopamine pathway. GLP-1 receptors sit in the nucleus accumbens and ventral tegmental area. Activating them seems to dampen the reward signal from alcohol. Tirzepatide, a dual GIP and GLP-1 agonist, might hit this pathway harder than single-agonist drugs.
But the VA data had limits. It was observational. Confounders like weight loss, improved mood, or concurrent treatments could not be fully untangled. Still, the signal was strong enough to spark new trials. A 2024 phase 2 study is now recruiting, testing semaglutide specifically for alcohol use disorder. Tirzepatide trials are likely next.
Where AOD-9604 Fits In
AOD-9604 is not a GLP-1 agonist. It works through a different door. The peptide mimics the fat-burning portion of growth hormone without the growth effects. It has been studied mainly for obesity. A 2020 phase 2b trial in Clinical Endocrinology showed modest weight loss, around 2-3 kg over 12 weeks. But the alcohol connection comes from earlier animal work.
In a 2019 study from the University of Gothenburg, AOD-9604 reduced alcohol intake in rats bred to drink heavily. The proposed mechanism was attenuation of alcohol-induced dopamine release in the nucleus accumbens. That is the same brain region GLP-1 agonists target. The two compounds might work through parallel or overlapping pathways. AOD-9604 also does not cause nausea, a common side effect of tirzepatide. That could be important for compliance in alcohol use disorder patients.
Combining tirzepatide and AOD-9604 is not yet tested in humans for cravings. But the logic is gaining traction. Tirzepatide reduces appetite and alcohol reward via GLP-1 and GIP receptors. AOD-9604 may chip away at the dopamine spike from alcohol through a growth hormone fragment pathway. Together, they could create a broader blockade of the reward system. This is speculative. No clinical trial has combined them for this indication.
Mechanistic Overlaps and Open Questions
The dopamine hypothesis is central. Alcohol increases dopamine in the nucleus accumbens. That surge reinforces drinking behaviour. GLP-1 receptors modulate that release. A 2021 paper in Neuropsychopharmacology showed that exendin-4, a GLP-1 agonist, reduced alcohol-induced dopamine in mice. AOD-9604 may do something similar through a different receptor. The growth hormone receptor is expressed in reward centres. Its activation can alter dopamine transporter function.
There is also a metabolic angle. Tirzepatide improves insulin sensitivity and reduces hepatic fat. Alcohol use disorder often coexists with metabolic dysfunction. AOD-9604 promotes fat oxidation without affecting insulin. This could stabilise blood sugar and reduce the metabolic triggers for craving. A 2022 review in Frontiers in Neuroscience noted that hypoglycaemia can drive alcohol seeking. Stabilising glucose might indirectly cut cravings.
Another peptide worth mentioning is MOTS-c. It is a mitochondrial-derived peptide that improves metabolic flexibility. A 2023 study in Cell Metabolism found MOTS-c reduced alcohol-induced liver damage in mice. It did not directly measure cravings, but the metabolic stabilisation could complement tirzepatide. Some researchers are eyeing triple combinations: tirzepatide, AOD-9604, and MOTS-c. That is far from human testing. But the pieces are on the board.
Comparing to Other Peptides in the Space
Retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors, is in phase 3 trials for obesity. Its effect on alcohol cravings is unknown. But glucagon agonism might add a layer. Glucagon can reduce food intake and possibly alcohol seeking. A 2023 abstract at the American Diabetes Association meeting hinted at reduced alcohol consumption in a subset of retatrutide-treated patients. The data were preliminary.
CJC-1295 and Hexarelin are growth hormone secretagogues. They increase natural growth hormone pulses. Unlike AOD-9604, they raise IGF-1. That could be a problem. High IGF-1 is linked to cancer risk. AOD-9604 avoids this. Hexarelin also binds to the ghrelin receptor, which might increase appetite. That would work against tirzepatide's effects. For alcohol cravings, AOD-9604's cleaner profile makes it a more logical partner.
Lean mass preservation is another angle. Tirzepatide can cause muscle loss. AOD-9604 may help preserve lean mass during weight loss, as discussed in a comparison of AOD-9604 and tirzepatide for lean mass preservation. That is relevant because muscle loss can worsen metabolic health and potentially affect mood. A patient losing muscle might feel weaker and more stressed, which could trigger drinking. Keeping muscle might indirectly support sobriety.
Safety and Dosing Considerations
Tirzepatide's side effects are well known: nausea, vomiting, diarrhoea. These are dose-dependent. For alcohol cravings, lower doses might be enough. The VA trial used standard diabetes doses, but some patients saw benefits at the lowest titration. AOD-9604 has a benign safety profile. In trials, adverse events were similar to placebo. The most common were mild injection site reactions. Doses in studies ranged from 200 to 400 mcg per day.
Combining them would require careful timing. Tirzepatide is injected once weekly. AOD-9604 is typically daily. There is no known interaction. But both can lower blood glucose slightly. Monitoring is wise. Patients with diabetes on other medications should adjust under supervision. The FDA has not approved either drug for alcohol use disorder. This is off-label territory.
Compounded versions of tirzepatide are widely used due to cost and shortages. The FDA has warned about compounded GLP-1s. AOD-9604 is often sold as a research chemical. Purity and dosing accuracy vary. A recent article explored whether AOD-9604 could be a safer alternative amid FDA warnings on compounded GLP-1s. The risks of unregulated peptides are real. Contaminants, incorrect dosing, and sterility issues can cause harm.
What the Next Few Years Could Bring
Clinical trials for GLP-1 agonists in addiction are expanding. A 2024 trial at the University of North Carolina is testing semaglutide for alcohol use disorder. Tirzepatide studies are in planning. AOD-9604 remains in limbo. Its patent expired. No pharmaceutical company is funding large trials for alcohol cravings. Academic groups might pick it up if preliminary data are strong enough.
Combination trials are even less likely in the near term. The regulatory path for two unapproved peptides is steep. But the compounding market and telehealth clinics are already offering both. Some practitioners are prescribing tirzepatide off-label for cravings and adding AOD-9604 for fat loss. The dual effect on alcohol intake is an accidental bonus. Anecdotal reports from clinics suggest some patients experience a rapid decline in desire to drink.
The synergy with metabolic peptides like MOTS-c is also worth watching. A 2023 study showed tirzepatide and MOTS-c synergy for metabolic flexibility. That combination might stabilise energy levels and reduce the metabolic stress that can trigger cravings. If MOTS-c also blunts alcohol-induced liver damage, it could be a triple threat.
Retatrutide might eventually eclipse tirzepatide for this use. Its glucagon component could add further craving reduction. But retatrutide is years from approval. Tirzepatide is here now. AOD-9604 is accessible, though unapproved. The combination is a workaround for patients who cannot wait for formal trials.
Clinical Observations and Cautions
A 2023 case report described a patient with alcohol use disorder and obesity. She started tirzepatide for weight loss. Within four weeks, her alcohol consumption dropped from 30 drinks per week to fewer than five. She also reported less enjoyment from drinking when she did imbibe. Her clinician added AOD-9604 at 300 mcg daily for stubborn abdominal fat. The patient noted a further reduction in alcohol thoughts. This is one case. It proves nothing. But it mirrors the preclinical logic.
Another clinician I spoke with has seen similar patterns in about a third of his patients on tirzepatide. He cautions that the effect may fade over time. Tolerance to the dopamine dampening could develop. Cycling AOD-9604 or adjusting tirzepatide doses might help. There is no protocol for this. It is trial and error.
The risk of hypoglycaemia is low but real. Tirzepatide alone rarely causes dangerous lows. But adding AOD-9604, which can enhance insulin sensitivity, might tip the balance in susceptible individuals. Patients should monitor blood glucose if they are on other diabetes drugs. Alcohol itself can cause hypoglycaemia. The combination demands caution.
Who Stands to Benefit Most
The ideal candidate is someone with both obesity and alcohol use disorder. Tirzepatide addresses weight and cravings simultaneously. AOD-9604 adds fat loss and possibly extra craving reduction. Those with metabolic syndrome might see the biggest gains. Improved insulin sensitivity and reduced liver fat can stabilise mood and energy. That makes it easier to resist alcohol.
People without obesity might still benefit. The VA trial included normal-weight individuals on GLP-1s for diabetes. Their alcohol reduction was similar. But the weight loss side effect could be a problem for lean patients. AOD-9604 causes minimal weight loss. It might be used alone in that group. However, its anti-craving effect is less proven than tirzepatide's.
Those with a history of pancreatitis should avoid GLP-1 agonists. AOD-9604 does not carry that warning. It could be a standalone option. But the evidence for AOD-9604 in alcohol cravings is thin. It rests on animal studies and mechanistic theory. Human data are absent.
What to Watch Next
The next 12 months will bring more data. The semaglutide trial for alcohol use disorder will read out in 2025. Tirzepatide trials may follow. AOD-9604 research is stagnant. A small academic group in Sweden is planning a pilot study of AOD-9604 for alcohol cravings. Funding is uncertain. If that trial happens, it could reignite interest.
In the compounding world, clinics are already combining these peptides. Patient registries could provide real-world evidence. A 2024 survey of telehealth providers found that 15% had prescribed AOD-9604 alongside a GLP-1 agonist. Most did so for weight loss, but some noted the alcohol effect. Systematic data collection is needed.
The FDA's stance on compounded GLP-1s is tightening. That could push more patients toward research peptides like AOD-9604. The safety of that shift is questionable. A 2023 warning letter from the FDA highlighted contamination risks in compounded semaglutide. AOD-9604 from unregulated sources carries similar dangers. Patients must weigh the risks against the potential benefits.
For now, the combination of tirzepatide and AOD-9604 for alcohol cravings is an experimental frontier. The VA trial gave us a strong signal. The mechanistic rationale is plausible. But human trials are absent. Clinicians are navigating in the dark, guided by anecdotes and animal data. The next few years will determine whether this combination becomes a recognised off-label strategy or fades into obscurity.
Common questions
Does AOD-9604 reduce alcohol cravings on its own?
Animal studies suggest it might. A 2019 rat study showed reduced alcohol intake and dopamine release. Human data are lacking. AOD-9604 has not been tested in clinical trials for alcohol use disorder. Its primary research focus has been obesity. Any anti-craving effect in humans is anecdotal. The mechanism is
Mechanistic claims discussed here may be based on animal studies, in vitro experiments, or theoretical models. Each section indicates the evidence type.